A 62-year-old woman with a new diagnosis of breast cancer.
Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Mass 02215, USA. scome@bidmc.harvard.edu
Steven E
SE
Come
D000730:Androstadienes / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000628:therapy*; D018275:Carcinoma, Lobular / Q000175:diagnosis / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003657:Decision Making; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D011379:Prognosis; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*
D000730:Androstadienes; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; C056516:exemestane